Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
Better treatments for hepatitis B and C and a lack of such advances for fatty liver or alcoholic liver disease are driving outcomes.
A look at the supply chain that results in very high costs for HIV and hepatitis C medications.
Two new treatments have hit the market, offering more options for those with genotypes 3 and 4.
The American Association for the Study of Liver Diseases has updated the treatment guidelines for hepatitis C.
New HCV treatment boasts over 90 percent cure rates, costs $84,000 for in the United States.
In a recent letter, the politician notes that the VA has stopped enrolling HCV-positive veterans because of budget constraints.
This marks a 15-fold increase for liver disease drugs since new HCV therapies started rolling out in 2013.
While highly expensive, treating hepatitis C with the combination of Sovaldi and Olysio is still cheaper per cure than treating with interfer...
Will a breakthrough hep C drug also break the bank?
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.